Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc. focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome. The company’s products in the clinical pipeline include JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-8, a formulation incorporating a benzodiazepine, for the treatment of acute repetitive seizure clusters in refractory epilepsy patients. Its pipeline also comprise JZP-7, a formulation incorporating a dopamine agonist for the treatment of restless legs syndrome; and JZP-2, a formulation of a benzodiazepine for the acute treatment of panic attacks associated with panic disorder. The company has a product development and license agreement with Antares Pharma, Inc. Jazz Pharmaceuticals was founded in 2003 and is headquartered in Palo Alto, California.
Milestones
Videos
Screenshots
Stock Price
Sources
-
Jazz Pharma Agrees To Buy EUSA Pharma For $650M (pevc.dowjones.com) [edit]
